1. Home
  2. KRYS vs TCBI Comparison

KRYS vs TCBI Comparison

Compare KRYS & TCBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • TCBI
  • Stock Information
  • Founded
  • KRYS 2015
  • TCBI 1996
  • Country
  • KRYS United States
  • TCBI United States
  • Employees
  • KRYS N/A
  • TCBI N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • TCBI Major Banks
  • Sector
  • KRYS Health Care
  • TCBI Finance
  • Exchange
  • KRYS Nasdaq
  • TCBI Nasdaq
  • Market Cap
  • KRYS 4.7B
  • TCBI 3.9B
  • IPO Year
  • KRYS 2017
  • TCBI N/A
  • Fundamental
  • Price
  • KRYS $183.36
  • TCBI $84.72
  • Analyst Decision
  • KRYS Strong Buy
  • TCBI Hold
  • Analyst Count
  • KRYS 9
  • TCBI 12
  • Target Price
  • KRYS $203.22
  • TCBI $83.25
  • AVG Volume (30 Days)
  • KRYS 384.0K
  • TCBI 392.5K
  • Earning Date
  • KRYS 11-03-2025
  • TCBI 10-16-2025
  • Dividend Yield
  • KRYS N/A
  • TCBI N/A
  • EPS Growth
  • KRYS 36.22
  • TCBI N/A
  • EPS
  • KRYS 4.91
  • TCBI 2.50
  • Revenue
  • KRYS $359,205,000.00
  • TCBI $936,954,000.00
  • Revenue This Year
  • KRYS $34.33
  • TCBI $47.34
  • Revenue Next Year
  • KRYS $47.84
  • TCBI $9.49
  • P/E Ratio
  • KRYS $37.38
  • TCBI $33.83
  • Revenue Growth
  • KRYS 116.08
  • TCBI N/A
  • 52 Week Low
  • KRYS $122.80
  • TCBI $59.37
  • 52 Week High
  • KRYS $207.84
  • TCBI $94.61
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 76.57
  • TCBI 46.42
  • Support Level
  • KRYS $158.08
  • TCBI $82.50
  • Resistance Level
  • KRYS $183.36
  • TCBI $87.67
  • Average True Range (ATR)
  • KRYS 6.02
  • TCBI 2.12
  • MACD
  • KRYS 2.37
  • TCBI -0.30
  • Stochastic Oscillator
  • KRYS 99.31
  • TCBI 40.44

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About TCBI Texas Capital Bancshares Inc.

Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.

Share on Social Networks: